Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Year: 2021
Type: review
Source: Pharmacological Research
Author: Robert Roskoski
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: covalent inhibitors, protein kinase inhibitors, Michael addition, cysteine thiolate, ibrutinib, Bruton's tyrosine kinase, acalabrutinib, zanubrutinib, afatinib, dacomitinib, osimertinib, neratinib, epidermal growth factor receptor, non-small cell lung cancer, HER2-positive breast cancer, mantle cell lymphoma, FDA-approved drugs
Open Access status: closed
OpenAlex ID: W3120861427
